US Tariffs on pharma: What are the potential impact on Indian drugmakers

US tariffs on pharmaceutical imports by the US President Donald Trump have sparked concerns within India’s pharma sector, a global leader in affordable generic drug supplies.

In an exclusive interaction with ETNow, Vishal Manchanda, an analyst at Systematix Group, shared his expert insights on the possible outcomes for Indian drugmakers, underscoring both the risks and opportunities that await investors monitoring key pharma stocks such as Sun Pharma, Cipla, and Dr. Reddy’s Laboratories.

Manchanda stressed that tariffs would have far-reaching consequences for both countries. He pointed out that the United States, with limited domestic manufacturing capacity, relies heavily on Indian generics for affordable healthcare.

“Tariffs, if imposed, will be harmful to both countries. The US lacks the capacity for domestic production, and no alternative matches India’s cost-efficient supply of generics,” he stated.

The outlook for Indian pharmaceutical stocks presents a mixed scenario.

Manchanda highlighted that leading firms like Sun Pharmaceutical, Cipla, and Dr. Reddy’s Laboratories could face headwinds in FY27, with pricing pressures and margin erosion likely to dent US market earnings.

However, despite these challenges, India’s domestic market remains robust, with a projected growth of 9% annually. Emerging markets are also expected to expand by 8-11%, offering a buffer against US slowdowns.

To reduce dependence on the US market, Indian pharma companies are actively exploring new avenues. Manchanda noted increased investments in biosimilars, complex generics, and digital healthcare solutions to diversify revenue streams and reduce US exposure.

While potential US tariffs may pose short-term profitability risks for Indian exporters, strong domestic demand and global diversification strategies could drive long-term sector growth.

Related Posts

  • Pharma
  • July 16, 2025
  • 140 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 47 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Famous Vaidyaratnam Ayurveda Clinic in Delhi is now more Accessible to Patients

Famous Vaidyaratnam  Ayurveda  Clinic in Delhi is now more Accessible to Patients